Table 1.
Type of theranostic nanomedicine |
Material (s) | Therapeutic agent | Diagnostic agent | Size | Targeting agent | Advancement | Reference |
---|---|---|---|---|---|---|---|
Drug-polymer conjugates | HPMA | 64Cu | 64Cu | N.A. | RGD | Cancer imaging and radiochemo-therapy | 39 |
Polymeric nanoparticles |
PLA-TPGS | Docetaxel | Quantum dots | ~ 250nm | Folic acid | Co-delivery of docetaxel and quantum dots | 59 |
Solid lipid nanoparticles |
Low-density lipoprotein, Cholesterol |
Paclitaxel/ siRNA |
Quantum dots | ~ 130nm | cRGD | Multimodal therapy |
66 |
Dendrimers | Polypropyleni-mine | Phthalocyanines | Phthalo cyanines |
~ 62nm | LHRH | Delivery of single theranostic agent | 75 |
Liposomes | TPGS, Phospholipids, Cholesterol |
Docetaxel | Quantum dots | ~ 210nm | Folic acid | Co-delivery of docetaxel and quantum dots | 88 |
Micelles | TPGS | Iron oxide nanoparticles |
Iron oxide nanoparticles | ~ 178nm | Passive | Delivery of single theranostic agent | 108 |
Gold nanoparticles |
Gold nanoparticles | DOX | Gold nanoparticles |
~ 55nm | CPLGLAGG peptide | Stimulus responsive drug release | 120 |
Carbon nanomaterials |
SWCNTs | Intrinsic property | Intrinsic property | Length of ~ 140nm |
Passive | Self photolumines-cent and photothermal property | 131 |